Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation

The BCR-ABL fusion protein with strong tyrosine kinase activity is one of the molecular biological bases of leukemia. Imatinib (Gleevec), a specific targeted drug for the treatment of chronic myeloid leukemia (CML), was developed for inhibiting the kinase activity of the BCR-ABL fusion protein. Desp...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Han-Qing, Gao, Feng-Hou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584333/
https://www.ncbi.nlm.nih.gov/pubmed/31258755
http://dx.doi.org/10.7150/jca.29528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584333/
https://www.ncbi.nlm.nih.gov/pubmed/31258755
http://dx.doi.org/10.7150/jca.29528

Ejemplares similares